Questa pagina è stata tradotta automaticamente e l'accuratezza della traduzione non è garantita. Si prega di fare riferimento al Versione inglese per un testo di partenza.

Personalized Virtual Environments for Managing Responsive Behaviors in Cognitively Impaired Patients: A Feasibility Study (iEMBRACE)

10 novembre 2026 aggiornato da: Susanna Pardini, Fondazione Bruno Kessler

Personalized Virtual Environments for Patients With Cognitive Impairment Exhibiting Responsive Behaviors: Proof-of-Concept and Feasibility Study

The goal of this feasibility study is to explore the feasibility of using realistic, customizable virtual reality (VR) environments in response to the onset of Responsive Behaviors in elderly residents with cognitive impairment.

Specifically, the study will assess;

  • feasibility through acceptance metrics (including recruitment rate, adherence rate, attrition rate, and tolerance to the intervention);
  • safety (monitoring for adverse effects related to VR headset use);
  • user engagement, enjoyment, and overall experience.

Participants will be exposed to three VR sessions conducted before, during, or after a situation deemed activating (e.g., personal hygiene activities). Operators will conduct a baseline assessment to identify specific moments when the participant experiences responsive behaviors. Additionally, operators may administer the Oculus VR headset when responsive behaviors occur outside of baseline-identified moments.

Panoramica dello studio

Stato

Completato

Descrizione dettagliata

Study Site and Environment: Data collection will occur at the Azienda Pubblica di Servizi alla Persona "Margherita Grazioli" in Povo, Trento. The experimental setup will be free from external interference to minimize distractions and ensure a smooth study process. The study will be conducted in familiar, ecologically relevant settings within APSP, selecting environments likely to stimulate activation states in participants.

Duration and Procedure: The study is expected to last six months. Each participant will undergo at least three VR sessions about situations that may trigger activation, such as personal hygiene activities. A baseline assessment will pinpoint specific times when participants exhibit responsive behaviors. Additionally, VR sessions may be initiated if responsive behaviors arise outside the predicted times using the Oculus headset.

Procedure and Timing for Each VR Session:

Preliminary Assessment (Participant Selection) (~30 minutes):

Participants are selected based on inclusion/exclusion criteria and provided with informed consent.

Information is collected from clinical records and updated based on the participant's condition.

An initial assessment examines responsive behaviors' type, frequency, and timing using demographic information, FAST, NPI, and CMAI.

Pre-Session Evaluation (T0) (~15 minutes):

Assessments include pain, responsive behaviors, emotions, anxiety, pleasantness, and discomfort before VR use (using PAINAD and STAI-Y1).

Virtual Environment Selection (~5 minutes):

The operator selects the VR environment for the participant through a smartphone linked to the Oculus headset via WiFi.

Procedure Explanation and Contextualization (~5 minutes):

A brief overview of the session and VR setup is provided to the participant.

Familiarization with Oculus Headset (~1-2 minutes):

A brief period to help the participant acclimate to the VR headset.

VR Session and During-Session Evaluation (T1) (~8 minutes within tolerance):

The VR session is audio-visual recorded, with the operator noting participant behaviors and responses (using OERS, Observation Sheet, STAI-Y1, Ad Hoc Questionnaire, PAINAD, and DataSheet2).

Post-Session Evaluation (T2) (~15 minutes):

Pain, responsive behaviors, emotions, anxiety, pleasantness, and discomfort are re-evaluated (using PAINAD, DataSheet2, Ad Hoc Questionnaire, STAI-Y1, OERS, NPT-ES, and VRSQ).

Final Evaluation (T3) (~10 minutes):

After all sessions, a final assessment using the Cohen-Mansfield Agitation Inventory (CMAI) is conducted.

Tipo di studio

Interventistico

Iscrizione (Effettivo)

10

Fase

  • Non applicabile

Contatti e Sedi

Questa sezione fornisce i recapiti di coloro che conducono lo studio e informazioni su dove viene condotto lo studio.

Luoghi di studio

      • Trento, Italia, 38123
        • APSP ''Grazioli''

Criteri di partecipazione

I ricercatori cercano persone che corrispondano a una certa descrizione, chiamata criteri di ammissibilità. Alcuni esempi di questi criteri sono le condizioni generali di salute di una persona o trattamenti precedenti.

Criteri di ammissibilità

Età idonea allo studio

18 anni e precedenti (Adulto, Adulto più anziano)

Accetta volontari sani

No

Sessi ammissibili allo studio

Tutto

Descrizione

Inclusion Criteria:

  • Adults over 18 years of age.
  • Native Italian speakers.
  • Can provide written informed consent for study participation or have a legal guardian who can give consent on their behalf.

Exclusion Criteria:

  • Presence of any psychiatric diagnoses as recorded in medical records.
  • A total score of ≥ 40 on the Neuropsychiatric Inventory (NPI) indicates neuropsychiatric symptoms.
  • A partial NPI score > 6 in the domains of agitation/aggression or delusions.
  • Enrollment in palliative care services.
  • Severe neurological damage, a positive diagnosis of epilepsy, or having first-degree relatives diagnosed with epilepsy.
  • Presence of a cardiac pacemaker or other metallic devices.
  • Infectious or gastrointestinal disorders.
  • Open facial wounds, motor or visual impairments, or neuromuscular pain that would prevent using the Oculus VR headset.
  • Refusal to consent, either by the individual or their legal representative, for study participation.

Piano di studio

Questa sezione fornisce i dettagli del piano di studio, compreso il modo in cui lo studio è progettato e ciò che lo studio sta misurando.

Come è strutturato lo studio?

Dettagli di progettazione

  • Scopo principale: Fattibilità del dispositivo
  • Assegnazione: N / A
  • Modello interventistico: Assegnazione di gruppo singolo
  • Mascheramento: Nessuno (etichetta aperta)

Armi e interventi

Gruppo di partecipanti / Arm
Intervento / Trattamento
Sperimentale: Virtual Reality group

Participants will undergo three VR exposure sessions using Oculus headsets, presenting a virtual environment with realistic natural stimuli or customized environments tailored to individual preferences and valued activities. For each environment, auditory (e.g., animal sounds, wind rustling, type of music) and visual elements (e.g., presence of people, objects, or animals), as well as time of day and weather conditions, can be adjusted. The operator will customize the environment through a user-friendly smartphone app interface, enabling real-time parameter adjustments and content selection. During VR exposure, the operator can observe the participant's visual focus in real-time.

Individuals will participate in three VR sessions using Oculus headsets, experiencing virtual environments featuring realistic natural stimuli or custom settings tailored to their preferences and valued activities. Each environment allows for the adjustment of auditory elements (such as animal sounds, rustling wind, or specific music), visual elements (such as people, objects, or animals), and the time of day and weather conditions. The operator will use a user-friendly smartphone app to customize the environment, making real-time adjustments to settings and content. Throughout the VR experience, the operator can monitor the participant's visual focus in real-time.

Cosa sta misurando lo studio?

Misure di risultato primarie

Misura del risultato
Misura Descrizione
Lasso di tempo
Fattibilità basata sul punto di vista dell'operatore sanitario utilizzando Focus Group
Lasso di tempo: Dall'arruolamento alla fine del trattamento a 3 settimane
Dall'arruolamento alla fine del trattamento a 3 settimane
Feasibility based on the health staff operator perspective using the System Usability Scale (SUS)
Lasso di tempo: From enrollment to the end of treatment at 3 weeks

The SUS scale permitted the obtaining of information about the system's usability. The SUS range raw score from 0 to 100.

From enrollment to the end of treatment at 3 weeks
Feasibility using an Ad-hoc questionnaire
Lasso di tempo: From enrollment to the end of treatment at 3 weeks

The ad-hoc questionnaire permitted information about usability, engagement, satisfaction, and pleasure during exposure to the VR environment, as well as feelings and relaxation. The questionnaire is composed of 30 items based on a Likert scale from 1 to 5 (range score from 0 to 4), 15 items based on a Likert scale from 1 to 4 (range score from 0 to 3), and five open-ended questions.

From enrollment to the end of treatment at 3 weeks
Feasibility using the Non-pharmacological Therapy Experience Scale (NPT-ES)
Lasso di tempo: From enrollment to the end of treatment at 3 weeks

The NPT-ES permitted obtaining information about the subjective experience during the administration of non-pharmacological therapy. Five items are assessed on a Likert scale from 0 to 3. The total raw score is from 0 to 15.

From enrollment to the end of treatment at 3 weeks

Misure di risultato secondarie

Misura del risultato
Misura Descrizione
Lasso di tempo
Assessment of the Responsive Behaviors administering the COHEN MANSFIELD - AGITATION INVENTORY (CMAI)
Lasso di tempo: From enrollment to the end of treatment at 3 weeks

The CMAI was permitted to obtain information about the frequencies of 29 different responsive behaviors based on a Likert scale from 0 to 6. The total raw score is from 0 to 174.

From enrollment to the end of treatment at 3 weeks
Assessment of the Responsive Behaviors administering the Functional Assessment Staging Tool (FAST)
Lasso di tempo: From enrollment to the end of treatment at 3 weeks

The FAST is a scale that permits the definition of the severity of functional impairment related to a diagnosis of cognitive impairment. It comprises seven degrees of severity and is assessed by the clinical health staff based on the anamnestic information.

From enrollment to the end of treatment at 3 weeks
Investigation of Adverse Symptoms Associated with Exposure to the Virtual Reality Device using the Virtual Reality Symptoms Questionnaire (VRSQ)
Lasso di tempo: From enrollment to the end of treatment at 3 weeks

The VRSQ assesses the general and eye-related physical symptoms of exposure to a virtual reality environment. The score assigned to each item ranges from 0 to 6, with a maximum total score of 84 (48 for general symptoms and 36 for eye symptoms). Higher scores represent worse symptoms, with 0 corresponding to no adverse effects and 84 to serious adverse effects.

From enrollment to the end of treatment at 3 weeks
Pain experience assessment using the Pain Assessment in Advanced Dementia (PAINAD)
Lasso di tempo: From enrollment to the end of treatment at 3 weeks

The PAINAD provides a method of analyzing the pain experienced by people with dementia. The total score ranges from 0-10 points.

From enrollment to the end of treatment at 3 weeks
Assessment of the pharmacotherapy administration and the users'behaviors before or during the VR sessions using the DataSheet 2
Lasso di tempo: From enrollment to the end of treatment at 3 weeks

DataSheet 2 permits obtaining information about the administration of pharmacotherapy before, during, or after the VR exposure based on three open-ended questions filled out by the health staff operator that administers the experimental procedure. Moreover, the scale permitted information about the user's behavior during the VR exposure to be assessed by the health staff operator based on five questions on a Likert scale from 0 to 3 (Total raw score from 0 to 15).

From enrollment to the end of treatment at 3 weeks
Assessment of the state-anxiety using the State-Trait Anxiety Inventory-Y1 (STAI-Y1)
Lasso di tempo: From enrollment to the end of treatment at 3 weeks

The modified version of the (STAI-Y1), inspired by Appel et al.2021, was administered in this study to obtain information on the state-anxiety level and other types of emotions individuals experienced before and after the VR session. The current study will investigate relaxation, worry/anxiety, sadness, tightness, annoyance, and anger explicitly. The scale is administered as an interview based on a 5-point Likert scale from 1 (not at all) to 5 (a lot).

From enrollment to the end of treatment at 3 weeks
Emotional and behavioral assessment using the Observed Emotion Rating Scale (OERS)
Lasso di tempo: From enrollment to the end of treatment at 3 weeks

The OERS assess the presence and frequency of negative emotions (fear, anxiety, anger, and sadness) and positive (pleasure) feelings experienced during the session based on a scale from 1 to 5 (1: "undetected emotion"; 2: "emotion observed for less than 16 s"; 3: "emotion observed for 16-59 s"; 4: "emotion observed for 1-5 min"; 5: "emotion observed for more than 5 min").

From enrollment to the end of treatment at 3 weeks

Altre misure di risultato

Misura del risultato
Lasso di tempo
Valutazione delle caratteristiche socio-demografiche mediante la scheda Socio-demografica
Lasso di tempo: Dall'arruolamento alla fine del trattamento a 3 settimane
Dall'arruolamento alla fine del trattamento a 3 settimane

Collaboratori e investigatori

Qui è dove troverai le persone e le organizzazioni coinvolte in questo studio.

Pubblicazioni e link utili

La persona responsabile dell'inserimento delle informazioni sullo studio fornisce volontariamente queste pubblicazioni. Questi possono riguardare qualsiasi cosa relativa allo studio.

Studiare le date dei record

Queste date tengono traccia dell'avanzamento della registrazione dello studio e dell'invio dei risultati di sintesi a ClinicalTrials.gov. I record degli studi e i risultati riportati vengono esaminati dalla National Library of Medicine (NLM) per assicurarsi che soddisfino specifici standard di controllo della qualità prima di essere pubblicati sul sito Web pubblico.

Studia le date principali

Inizio studio (Effettivo)

15 maggio 2025

Completamento primario (Effettivo)

28 novembre 2025

Completamento dello studio (Effettivo)

28 novembre 2025

Date di iscrizione allo studio

Primo inviato

12 novembre 2024

Primo inviato che soddisfa i criteri di controllo qualità

15 novembre 2024

Primo Inserito (Effettivo)

18 novembre 2024

Aggiornamenti dei record di studio

Ultimo aggiornamento pubblicato (Effettivo)

12 novembre 2026

Ultimo aggiornamento inviato che soddisfa i criteri QC

10 novembre 2026

Ultimo verificato

1 novembre 2026

Maggiori informazioni

Termini relativi a questo studio

Piano per i dati dei singoli partecipanti (IPD)

Hai intenzione di condividere i dati dei singoli partecipanti (IPD)?

INDECISO

Informazioni su farmaci e dispositivi, documenti di studio

Studia un prodotto farmaceutico regolamentato dalla FDA degli Stati Uniti

No

Studia un dispositivo regolamentato dalla FDA degli Stati Uniti

No

prodotto fabbricato ed esportato dagli Stati Uniti

No

Queste informazioni sono state recuperate direttamente dal sito web clinicaltrials.gov senza alcuna modifica. In caso di richieste di modifica, rimozione o aggiornamento dei dettagli dello studio, contattare register@clinicaltrials.gov. Non appena verrà implementata una modifica su clinicaltrials.gov, questa verrà aggiornata automaticamente anche sul nostro sito web .

Sottoscrivi